转移性非小细胞肺癌患者和肿瘤PD-L1 <1% 患者接受纳武利尤单抗加伊匹单抗一线治疗的长期生存结果：汇总分析

文章预览

SCI 31 October 2024 Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 < 1%: a Pooled Analysis （IF: Journal of Thoracic Oncology, 21） Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O’Byrne KJ, John T, Ciuleanu T-E, Schenker M, Caro RB, Nishio M, Cobo M, Lee J-S, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS, Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 < 1%: a Pooled Analysis, Journal of Thoracic Oncology (2024). Corresponding author:  Solange Peters, MD, PhD  Oncology Department  Lausanne University Hospital (CHUV)  Bugnon 46  1011 Lausanne, Switzerland  solange.peters@chuv.ch Introduction 介绍 Nivolumab plus ipilimumab–based treatment regimens have shown long term, durable efficacy ………………………………